[{"id":"70a14a13-f51d-4a8e-b7a5-ae3fdaedca67","acronym":"","url":"https://clinicaltrials.gov/study/NCT02788201","created_at":"2021-01-29T07:12:16.767Z","updated_at":"2024-07-02T16:36:38.979Z","phase":"Phase 2","brief_title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","source_id_and_acronym":"NCT02788201","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • sorafenib • paclitaxel • docetaxel • sunitinib • tamoxifen • cytarabine • bortezomib • doxorubicin hydrochloride • azacitidine • Jakafi (ruxolitinib) • oxaliplatin • irinotecan • Halaven (eribulin mesylate) • epirubicin • carmustine • Vumon (teniposide) • hydroxyurea • Zanosar (streptozocin)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 03/27/2017","start_date":" 03/27/2017","primary_txt":" Primary completion: 10/23/2019","primary_completion_date":" 10/23/2019","study_txt":" Completion: 10/23/2019","study_completion_date":" 10/23/2019","last_update_posted":"2020-11-06"}]